Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia

Journal of Infectious Diseases

Volumn 214, Issue 1, 2016, Pages 105-113

  Pasay, Cielo J ^a   Rockett, Rebecca ^b,c   Sekuloski, Silvana ^a   Griffin, Paul ^a,b,c,d   Marquart, Louise ^a   Peatey, Christopher ^e   Wang, Claire Y T ^c   O'Rourke, Peter ^a   Elliott, Suzanne ^d   Baker, Mark ^f   Möhrle, Jörg J ^g   McCarthy, James S ^a,b,d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Mater Medical Research Institute   (Australia)

^d Mater Research Institute   (Australia)

^e AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^f Medicaments pour Tous   (Switzerland)

^g Medicines for Malaria Venture   (Switzerland)

Author keywords

gametocytemia; malaria; P. falciparum; piperaquine clinical trial

Indexed keywords

ALANINE AMINOTRANSFERASE; PIPERAQUINE; ANTIMALARIAL AGENT; QUINOLINE DERIVATIVE;

ABDOMINAL CRAMP; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ANTIMALARIAL ACTIVITY; CHILL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GAMETOCYTE; GAMETOCYTEMIA; GENE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INDUCED BLOOD STAGE MALARIA; LETHARGY; LEUKOPENIA; MALARIA FALCIPARUM; MALE; MONOTHERAPY; NAUSEA; NONHUMAN; NORMAL HUMAN; PARASITE CLEARANCE; PARASITEMIA; PFS25 GENE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; ADOLESCENT; AUSTRALIA; CLINICAL TRIAL; DRUG EFFECTS; GAMETOGENESIS; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; AUSTRALIA; COHORT STUDIES; FEMALE; GAMETOGENESIS; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PILOT PROJECTS; PLASMODIUM FALCIPARUM; QUINOLINES; YOUNG ADULT;

EID: 84979248000     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw128     Document Type: Conference Paper

References (34)

1. Chen C. Development of antimalarial drugs and their application in China: a historical review. Infect Dis Poverty 2014; 3:9-19
2. The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisininpiperaquine: a pooled analysis of individual patient data. PLoS Med 2013; 10: e1001564
3. Muhindo MK, Kakuru A, Jagannathan P, et al. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J 2014; 13:32-40
4. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One 2014; 9:e84976
5. Tarning J, Lindegardh N, Lwin KM, et al. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob Agents Chemother 2014; 58:2052-8
6. Manning J, Vanachayangkul P, Lon C, et al. Randomized, double-blind, placebocontrolled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother 2014; 58:6056-67
7. Darpo B, Ferber G, Siegl P, et al. Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria. Br J Clin Pharmacol 2015; 80:706-15
8. Stein DS, Jain JP, Kangas M, et al. Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine. Antimicrob Agents Chemother 2015; 59:3493-500
9. Church LP, Le TP, Bryan JP, et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 1997; 175:915-20
10. Epstein JE, Rao S, Williams F, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 2007; 196:145-54
11. Roestenberg M, Bijker EM, Sim BKL, et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2013; 88:5-13
12. Cheng Q, Lawrence G, Reed C, et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg 1997; 57:495-500
13. McCarthy JS, Sekuloski S, Griffin PM, et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One 2011; 6:e21914
14. Marquart L, Baker M, O'Rourke P, McCarthy JS. Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative polymerase chain reaction. Antimicrob Agents Chemother 2015; 59:4249-59
15. Rockett RJ, Tozer SJ, Peatey C, et al. A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers. Malar J 2011; 10:1-6
16. Kaslow DC, Quakyi IA, Syin C, et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988; 333:74-6
17. Joice R, Narasimhan V, Montgomery J, et al. Inferring developmental stage composition from gene expression in human malaria. PLoS Comput Biol 2013; 9: e1003392
18. Piatkov I, Jones T, Rochester C. Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application. Pharmacogenomics 2009; 10:1987-94
19. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413-22
20. Cooper H, Hedges LV, Valentine JC. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation, 2009
21. Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013; 369:1381-2
22. Pybus BS, Marcsisin SR, Jin X, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J 2013; 12:212
23. Barnes KI, Little F, Mabuza A, et al. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J Infect Dis 2008; 197:1605-13
24. Sokhna CS, Trape JF, Robert V. Gametocytaemia in Senegalese children with uncomplicated falciparum malaria treated with chloroquine, amodiaquine or sulfadoxine+ pyrimethamine. Parasite 2001; 8:243-50
25. Robert V, Awono-Ambene HP, Le Hesran JY, Trape JF. Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. Am J Trop Med Hyg 2000; 62:210-6
26. Tjitra E, Suprianto S, Anstey NM. Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine and the combination of chloroquine plus sulfadoxine-pyrimethamine: implications for progression of anti-folate resistance. Trans R Soc Trop Med Hyg 2002; 96:434-7
27. Bousema JT, Gouagna LC, Drakeley CJ, et al. Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya. Malar J 2004; 3:18-23
28. Delves MJ, Ruecker A, Straschil U, et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob Agents Chemother 2013; 57:3268-74
29. Schneider P, Bousema JT, Gouagna LC, et al. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg 2007; 76:470-4
30. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67
31. Leang R, Barrette A, Bouth DM, et al. Efficacy of dihydroartemisininpiperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 2013; 57:818-26
32. Saunders DL, Vanachayangkul P, Lon C. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 2014; 371:484-5
33. Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 2016; 16:357-65
34. Rogerson SJ, Wijesinghe RS, Meshnick SR. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis 2010; 10:51-9